Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 1/2017

01-01-2017 | Original Article

Expression of Ku70 predicts results of radiotherapy in prostate cancer

Authors: Tomokazu Hasegawa, MD, Masanori Someya, MD, PhD, Masakazu Hori, MD, PhD, Yoshihisa Matsumoto, MD, PhD, Kensei Nakata, MD, Masanori Nojima, MD, PhD, Mio Kitagawa, MD, Takaaki Tsuchiya, MD, Naoya Masumori, MD, PhD, Tadashi Hasegawa, MD, PhD, Koh-ichi Sakata, MD, PhD

Published in: Strahlentherapie und Onkologie | Issue 1/2017

Login to get access

Abstract

Background and purpose

Therapeutic strategy for prostate cancer is decided according to T stage, Gleason score, and prostate-specific antigen (PSA) level. These clinical factors are not accurate enough to predict individual risk of local failure of prostate cancer after radiotherapy. Parameters involved with radiosensitivity are required to improve the predictive capability for local relapse.

Patients and methods

We analyzed 58 patients with localized adenocarcinoma of the prostate between August 2007 and October 2010 treated with 76 Gy of intensity-modulated radiotherapy (IMRT) as a discovery cohort and 42 patients between March 2001 and May 2007 treated with three-dimensional conformal radiotherapy (3D-CRT) as a validation cohort. Immunohistochemical examination for proteins involved in nonhomologous end-joining was performed using biopsy specimens.

Results

Ku70 expression was not correlated with various clinical parameters, such as the Gleason score and D’amico risk classification, indicating that Ku70 expression was an independent prognostic factor. The predictive value for PSA relapse was markedly improved after the combination of Gleason score and Ku70 expression, as compared with Gleason score alone. In patients treated with radiotherapy and androgen deprivation therapy (ADT), no relapses were observed in patients with Gleason score ≤7 or low Ku70 expression. In contrast, patients with Gleason score ≥8 and high Ku70 expression had high PSA relapse rates. In the validation cohort, similar results were obtained.

Conclusion

Treatment with 76 Gy and ADT can be effective for patients with Gleason score ≤7 or low Ku70 expression, but is not enough for patients with Gleason score ≥8 and high Ku70 expression and, thus, require other treatment approaches.
Literature
1.
2.
Hall EJ (2006) DNA strand breaks and chromosomal aberrations. In: Hall EJ, Giaccia AM (eds) Radiobiology for the radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 16–29
3.
4.
Lees-Miller SP (1996) The DNA-dependent protein kinase, DNA-PK: 10 years and no ends in sight. Biochem Cell Biol 74:503–512CrossRefPubMed
5.
Jeggo PA (1998) Identification of genes involved in repair of DNA double strand-breaks in mammalian cells. Radiat Res 150:S80–S91CrossRefPubMed
6.
Karanika S, Karantanos T, Li L et al (2015) DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 34(22):2815–2822CrossRefPubMed
7.
Ta HQ, Gioeli D (2014) The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocr Relat Cancer 21(5):R395–R407CrossRefPubMedPubMedCentral
8.
9.
Al-Ubaidi FL, Schultz N, Loseva O et al (2013) Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res 19(6):1547–1556CrossRefPubMed
10.
Goodwin JF, Kothari V, Drake JM et al (2015) DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis. Cancer Cell 28(1):97–113CrossRefPubMedPubMedCentral
11.
Zelefsky MJ, Fuks Z, Hunt M et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166(3):876–881CrossRefPubMed
12.
Someya M, Hori M, Tateoka K et al (2015) Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res 56:122–127CrossRefPubMed
13.
14.
Sakata K, Matsumoto Y, Tauchi H et al (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys 49(1):161–167CrossRefPubMed
15.
Kamder RP, Matsumoto Y (2010) Radiation-induced XRCC4 association with chromatin DNA analyzed by biochemical fractionation. J Radiat Res 51:303–313CrossRef
16.
Komuro Y, Watanabe T, Hosoi Y et al (2002) The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 95(6):1199–1205CrossRefPubMed
17.
Bouchaert P, Guerif S, Debiais C et al (2012) DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1179–1185CrossRefPubMed
18.
Stone NN, Potters L, Davis BJ et al (2009) Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73(2):341–346CrossRefPubMed
Metadata
Title
Expression of Ku70 predicts results of radiotherapy in prostate cancer
Authors
Tomokazu Hasegawa, MD
Masanori Someya, MD, PhD
Masakazu Hori, MD, PhD
Yoshihisa Matsumoto, MD, PhD
Kensei Nakata, MD
Masanori Nojima, MD, PhD
Mio Kitagawa, MD
Takaaki Tsuchiya, MD
Naoya Masumori, MD, PhD
Tadashi Hasegawa, MD, PhD
Koh-ichi Sakata, MD, PhD
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 1/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1023-7

Other articles of this Issue 1/2017

Strahlentherapie und Onkologie 1/2017 Go to the issue

Original Article

Patient-related quality assurance with different combinations of treatment planning systems, techniques, and machines

Literatur kommentiert

Kein Nachweis einer Ergebnisverbesserung der Salvage-Radiotherapie beim asymptomatischen biochemischen Prostatakarzinom rezidiv nach Prostatektomie durch additive Androgensuppression

Original Article

Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy

Original Article

Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails

Literatur kommentiert

Zeitintervall zwischen neoadjuvanter Radiochemotherapie und Operation beim Rektumkarzinom

Case Study

Post-transplant lymphoproliferative disorder in the pelvis successfully treated with consolidative radiotherapy